← boardnext 2026-08next 2027-02
KOD
Kodiak Sciences Incdistress 3/10 · well-funded / low risk$40.78-3%today-12% from 52w high
Metabolic / Obesity 1
Lead: Macular Edema Secondary to Inflammation
Revenue
pre-revenue
Liquidity
$170M
Runway
1.1 yrs
Shares 1y
+19%
Price & events
+45.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-1.1%
1W
+10.1%
1M
-9.8%
3M
+57.7%
6M
+491.0%
1Y
+1207.1%
2Y
-52.5%
5Y
-70.4%
All
Overview
- Market Cap
- $2.55B
- Volume
- 36.89K
- 52 Week Range
- $4.53 – $46.44
- Total Shares
- 62.58M
- Float Shares
- 39.28M
- Short %
- 26.95%
- % Held by Insiders
- 5.18%
- % Held by Institutions
- 99.64%
- RVOL
- 0.05x
- Beta
- 2.20
Pipeline stages · 2 programs
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KSI-101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept | Wet Age-related Macular Degeneration | — | active not recruiting |
| 2027-02 Estimated 50% readout ~2027-04-17 | Phase 3 | KSI-101 | Macular Edema Secondary to Inflammation | — | recruiting |
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 3 | KSI-101 | Macular Edema Secondary to Inflammation | — | recruiting |
| 2026-02-13 | Phase 3 | Tarcocimab | Diabetic Retinopathy | 255 | completed |
Catalyst news & presentations · 1
- 2026-08-12earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $63 (+54% upside) · 6 analysts
- 2026-05-11Chardan CapitalNeutral → Buy
- 2026-03-27HC Wainwright & Co.Buy
- 2026-03-27UBSBuy
- 2026-02-10HC Wainwright & Co.Buy
- 2026-01-22HC Wainwright & Co.Buy
- 2026-01-07UBSBuy
Competitors — Macular Edema Secondary to Inflammation
- none identified
Recent news
- 2026-07-18Form 4 Kodiak Sciences Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Kodiak Sciences Inc. (KOD) awards CFO 66,500 stock options - Stock Titan
- 2026-07-17Kodiak Sciences (KOD) awards CEO Perlroth 100,000 stock options - Stock Titan
- 2026-07-04Is Kodiak Sciences’ (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story? - simplywall.st
- 2026-07-02Form 4 Kodiak Sciences Inc For: 2 July By Investing.com - Investing.com Nigeria
- 2026-07-0217,731 options granted to Kodiak (NASDAQ: KOD) board director - Stock Titan
- 2026-07-02[Form 4] Kodiak Sciences Inc. Insider Trading Activity - Stock Titan
- 2026-07-02Director at Kodiak Sciences (KOD) receives 17,731 stock options award - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.